Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Sedation

Therapeutic area intelligence for Sedation with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
0
Companies
0

Companies

No related entities indexed yet.

Assets

dexmedetomidine →
ketamine →

Recent signals(3)

ClinicalJuly 23, 2026

Study Compares Topical Anesthesia to Propofol-Ketamine for GI Endoscopy

A clinical trial is underway to compare the efficacy and safety of a modified topical anesthesia technique against conventional intravenous sedation for upper gastrointestinal endoscopy.

ClinicalJuly 13, 2026

Trial on Low-Dose Remimazolam for Emergence Agitation in Oral Surgery

A randomized controlled trial is set to evaluate the impact of low-dose remimazolam on emergence agitation in oral surgery.

ClinicalJuly 1, 2026

Dexmedetomidine-esketamine combo may reduce delirium in ICU patients

A clinical trial is investigating the efficacy of a dexmedetomidine-esketamine combination to reduce delirium in ICU patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.